tiprankstipranks
ImmuneOnco’s IMM0306 Shows Promising Trial Results
Company Announcements

ImmuneOnco’s IMM0306 Shows Promising Trial Results

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541) has released an update.

Don't Miss Our Christmas Offers:

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has reported promising results from its Phase Ib/IIa clinical trial of IMM0306, a bispecific molecule for treating indolent lymphoma. The trial demonstrated an 84% overall response rate in follicular lymphoma patients, with a 100% rate in marginal zone lymphoma cases, showcasing significant efficacy. The company continues active enrollment and observation in this study.

For further insights into HK:1541 stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App